Glucose Monitors Can Help Type 2 Diabetics Who Don't Yet Need Insulin, Trial Shows - U.S. News & World Report

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Home » Progressive Dairy — Canada » How important is transition health in herds that manage reproduction with activity monitors? Reproductive management that prioritizes estrus detection by activity monitors can achieve comparable pregnancy rates and profit to systematic timed-A. I. programs, but this varies among herds. It can allow high estrus detection rates for re-insemination, and a proportion of cows can be bred based on estrus for first insemination, reducing the handling required in synchronization protocols. However, the probability of a cow being inseminated in estrus detected by activity monitors is associated with their health status during the transition and voluntary waiting periods. For all reproductive management programs, cows with health disorders have lower fertility than their healthy herdmates. Professor and Director of Dairy / University of GuelphRelatedImpact of diseases on estrus detectionThe first step to have a successful reproductive program based on activity monitor estrus detection is detecting cows in estrus.

A virtual e-health system (VIRTUES) was as safe and effective as standard care for monitoring the function of cardiac implantable electronic devices, with the benefit of cost savings and patient satisfaction. These were the main findings of the VIRTUES trials presented in a Hot Line session today at ESC Congress 2026. The use of pacemakers and implantable cardioverter defibrillators (ICDs) is increasing due to expanding indications and the aging population. Principal Investigator, Professor Ratika Parkash from Dalhousie University, Halifax, Canada, explained why the VIRTUES PM and ICD trials were carried out: "Globally, around 1.25 million people are implanted with devices like pacemakers every year. It is important to follow these patients over their lifetimes to check their devices are working well; however, this entails regular visits to specialist clinics, which can be burdensome for the patient and healthcare system. "

IntroductionType 2 diabetes (T2D) has emerged as one of the major public health and economic burdens of the 21st century, affecting more than 37 million people in the United States of America and more than 500 million people globally (~10.5%)1. As these shocking numbers continue to rise, the cost of caring for patients with diabetes and its complications is placing enormous strain on the global economy, totaling nearly $1 trillion dollars in economic impact2, despite the development of nearly a dozen new medications for disease management. As the scale of the problem grows exponentially, our fundamental understanding of the cellular and molecular mechanisms of T2D remains incomplete, limiting our ability to develop effective, targeted medications that address the underlying pathophysiology rather than the disease’s symptoms. T2D arises when insulin secretion is insufficient to compensate for progressive, sustained peripheral insulin resistance, leading to a systemic rise in glucose concentrations.